COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils
- PMID: 25007795
- PMCID: PMC4115214
- DOI: 10.1186/1471-2466-14-112
COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils
Abstract
Background: Eosinophilic airway inflammation is observed in 10-30% of COPD subjects. Whether increased eosinophils or impairment in their clearance by macrophages is associated with the severity and frequency of exacerbations is unknown.
Methods: We categorised 103 COPD subjects into 4 groups determined by the upper limit of normal for their cytoplasmic macrophage red hue (<6%), an indirect measure of macrophage efferocytosis of eosinophils, and area under the curve sputum eosinophil count (≥ 3%/year). Eosinophil efferocytosis by monocyte-derived macrophages was studied in 17 COPD subjects and 8 normal controls.
Results: There were no differences in baseline lung function, health status or exacerbation frequency between the groups: A-low red hue, high sputum eosinophils (n=10), B-high red hue, high sputum eosinophils (n=16), C-low red hue, low sputum eosinophils (n=19) and D- high red hue, low sputum eosinophils (n=58). Positive bacterial culture was lower in groups A (10%) and B (6%) compared to C (44%) and D (21%) (p=0.01). The fall in FEV1 from stable to exacerbation was greatest in group A (ΔFEV1 [95 % CI] -0.41 L [-0.65 to -0.17]) versus group B (-0.16 L [-0.32 to -0.011]), C (-0.11 L [-0.23 to -0.002]) and D (-0.16 L [-0.22 to -0.10]; p=0.02). Macrophage efferocytosis of eosinophils was impaired in COPD versus controls (86 [75 to 92]% versus 93 [88 to 96]%; p=0.028); was most marked in group A (71 [70 to 84]%; p=0.0295) and was inversely correlated with exacerbation frequency (r=-0.63; p=0.006).
Conclusions: Macrophage efferocytosis of eosinophils is impaired in COPD and is related to the severity and frequency of COPD exacerbations.
Figures



Similar articles
-
Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort.Lancet Respir Med. 2017 Dec;5(12):956-967. doi: 10.1016/S2213-2600(17)30432-0. Epub 2017 Nov 13. Lancet Respir Med. 2017. PMID: 29146301 Free PMC article.
-
Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.Lancet Respir Med. 2014 Nov;2(11):891-901. doi: 10.1016/S2213-2600(14)70187-0. Epub 2014 Sep 7. Lancet Respir Med. 2014. PMID: 25208464 Free PMC article. Clinical Trial.
-
Relationship between Blood and Induced Sputum Eosinophils, Bronchial Hyperresponsiveness and Reversibility of Airway Obstruction in Mild-to-Moderate Chronic Obstructive Pulmonary Disease.COPD. 2019 Dec;16(5-6):354-361. doi: 10.1080/15412555.2019.1675150. Epub 2019 Oct 21. COPD. 2019. PMID: 31631716
-
Eosinophilic airway inflammation in COPD.Int J Chron Obstruct Pulmon Dis. 2006;1(1):39-47. doi: 10.2147/copd.2006.1.1.39. Int J Chron Obstruct Pulmon Dis. 2006. PMID: 18046901 Free PMC article. Review.
-
Eosinophils in chronic obstructive pulmonary disease.Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251335800. doi: 10.1177/17534666251335800. Epub 2025 May 28. Ther Adv Respir Dis. 2025. PMID: 40434001 Free PMC article. Review.
Cited by
-
Eosinophilia and clinical outcome of chronic obstructive pulmonary disease: a meta-analysis.Sci Rep. 2017 Oct 18;7(1):13451. doi: 10.1038/s41598-017-13745-x. Sci Rep. 2017. PMID: 29044160 Free PMC article.
-
Eosinophilic and non-eosinophilic COPD patients with chronic respiratory failure: neutrophil-to-lymphocyte ratio as an exacerbation marker.Int J Chron Obstruct Pulmon Dis. 2017 Nov 23;12:3361-3370. doi: 10.2147/COPD.S147261. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 29200843 Free PMC article.
-
Role of Type2 Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease.J Clin Med. 2020 Aug 18;9(8):2670. doi: 10.3390/jcm9082670. J Clin Med. 2020. PMID: 32824775 Free PMC article. Review.
-
Eosinophilia Is a Favorable Marker for Pneumonia in Chronic Obstructive Pulmonary Disease.Tuberc Respir Dis (Seoul). 2024 Oct;87(4):465-472. doi: 10.4046/trd.2023.0174. Epub 2024 May 3. Tuberc Respir Dis (Seoul). 2024. PMID: 38710525 Free PMC article.
-
Outcome of SARS-CoV-2 reinfection depends on genetic background in female mice.Nat Commun. 2024 Nov 23;15(1):10178. doi: 10.1038/s41467-024-54334-7. Nat Commun. 2024. PMID: 39580470 Free PMC article.
References
-
- Eltboli O, Brightling CE. Eosinophils as diagnostic tools in chronic lung disease. Expert Rev Respir Med. 2013;7(1):33–42. - PubMed
-
- Barker BL, Brightling CE. Phenotyping the heterogeneity of chronic obstructive pulmonary disease. ClinSci (Lond) 2013;124(6):371–387. - PubMed
-
- Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, Pavord ID. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2000;356(9240):1480–1485. - PubMed
-
- Woolley KL, Gibson PG, Carty K, Wilson AJ, Twaddell SH, Woolley MJ. Eosinophil apoptosis and the resolution of airway inflammation in asthma. Am J Respir Crit Care Med. 1996;154(1):237–243. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases